Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 11—November 2014
Research

Drug-Resistant Candida glabrata Infection in Cancer Patients

Dimitrios Farmakiotis1, Jeffrey J. Tarrand, and Dimitrios P. KontoyiannisComments to Author 
Author affiliations: The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (D. Farmakiotis, J.J. Tarrand, D.P. Kontoyiannis); Baylor College of Medicine, Houston (D. Farmakiotis)

Main Article

Table 1

Basic demographic, clinical, and laboratory characteristics for 144 cancer patients with 146 episodes of Candida glabrata fungemia, MD Anderson Cancer Center, Houston, Texas, USA, March 2005–September 2013*

Characteristic No. (%)
Host
Age, y, mean (± SD), range 55.5 (± 14.52), 12–85
Male sex 74 (51.38)
Solid tumor† 98 (68.05)
Hematologic malignancy 46 (31.95)
Leukemia 22 (15.3)
Acute myeloid leukemia 17 (11.81)
Acute lymphoblastic leukemia 5 (3.47)
Lymphoma 14 (9.72)
Multiple myeloma 4 (2.77)
Myelodysplastic syndrome 2 (1.38)
Myelohyperplastic syndrome 4 (2.77)
Hematopoietic stem cell transplantation
16 (11.11)
Clinical disease
Intensive care unit stay 59 (40.41)
Mechanical ventilation 27 (18.49)
Presence of a central line 131 (89.72)
Total parenteral nutrition
 36 (24.65)
Recent (within 1 mo before the day of candidemia) drug exposures
Chemotherapy 69 (47.26)
Any corticosteroids 85 (58.21)
Antibacterial drugs 144 (98.63)
Azoles 44 (30.13)
Echinocandins
 32 (21.91)
Laboratory findings
Neutropenia, cells/μL
<500 28 (19.17)
100–500 9 (6.16)
<100 19 (13.14)
Lymphopenia, cells/μL
<500 86 (58.9)
<100 30 (20.54)
Monocytopenia, <100 cells/μL 39 (26.71)

*All parameters were present on the day of candidemia, defined as the day of blood culture collection. Data are presented as absolute numbers (%) unless otherwise indicated for normally distributed variables or median numbers (25th–75th percentile) for variables that were not normally distributed.
†Tumor types were as follows: 47 (32.63%) gastrointestinal, 12 (8.33%) gynecologic, 9 (6.25%) genitourinary, 6 (4.16%) breast, 6 (4.16%) lung, 3 (2.08%) thyroid, 4 (2.77%) sarcomas, 3 (2.08%) head and neck, 2 (1.38%) central nervous system, and 6 (4.16%) other.

Main Article

1Current affiliation: Harvard Medical School Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA

Page created: October 15, 2014
Page updated: October 15, 2014
Page reviewed: October 15, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external